Characteristics of Nondystrophic Myotonias

Completed

• Conditions: Myotonic Disorders; Nondystrophic Myotonias; Myotonia Congenita

• Registration Number: NCT00244413
• Lead Sponsor: Richard Barohn, MD

Brief Summary

Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. The purpose of this study is to better characterize the clinical features and symptoms of NDM.

Detailed Description

Nondystrophic myotonias are muscle disorders caused by abnormal muscle cell membrane proteins that affect the control of muscle fiber contraction. These disorders are extremely rare, and little is known about how to best treat the various subtypes of NDM. The purpose of this study is to characterize the clinical features and symptoms of NDM as well as to pair this data with specific NDM subtypes. In turn, this may lead to the development of improved treatments. The study will also establish clinical endpoints for use in future studies.

This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend a one-day outpatient study visit. Various baseline measurements will be collected, including demographics, medical history, and quality of life measures. Blood samples will be taken to evaluate laboratory values and genetic factors. Participants will undergo manual muscle testing (MMT), clinical myotonia assessments, and functional movement assessments. Routine nerve conduction studies and electromyography (EMG) will also be performed in order to test for the presence of myotonia in specific muscles. Annual follow-up evaluations will occur 1 and 2 years following the first study visit.

Study Timeline

• Study First Submitted: 2005-10-24
• Study First Submitted QC: 2005-10-24
• Study First Posted: 2005-10-26
• Study Start: 2006-02
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-05
• Last Update Posted: 2013-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 94

Inclusion Criteria

• Clinical symptoms or signs suggestive of myotonia
• Presence of myotonic potentials on electromyography (EMG)
• Persistence of symptoms and signs after discontinuation of medications that produce myotonia; such medications include fibric acid derivatives, hydroxymethylglutaryl CoA reductase inhibitors, chloroquine, and colchicine
• Absence of features suggestive of myotonic dystrophy, including ptosis, temporal wasting, mandibular weakness, cataracts occurring before age 50, and evidence of multisystem defects (cardiac conduction defects, hypogonadism)

Exclusion Criteria

• Any other neurologic condition that might affect the assessment of the study measurements

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Examine the frequency applicable events related to Nondystrophic Myotonia	Baseline - 3 yrs	We will measure by an interactive voice response to measure stiffness, pain, weakness, and fatigue.

Trial Locations

Locations (6)

University of Kansas Medical Center, Department of Neurology; 🇺🇸 Kansas City, Kansas, United States

Center for Neuromuscular Disease, Institute of Neurology and National Hospital for Neurology; 🇬🇧 London, United Kingdom

University of Rochester School of Medicine and Dentistry, Department of Neurology; 🇺🇸 Rochester, New York, United States

University of Texas Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States

London Health Sciences Centre, University Hospital; 🇨🇦 London, Ontario, Canada

Brigham & Women's Hospital, Department of Neurology; 🇺🇸 Boston, Massachusetts, United States